Published in J Pediatr Gastroenterol Nutr on July 01, 2013
A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis (FREE) | NCT03657771
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population (EoE) | NCT05176249
A Clinical Prediction Tool Identifies Cases of Eosinophilic Esophagitis Without Endoscopic Biopsy: A Prospective Study. Am J Gastroenterol (2015) 1.04
Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. J Allergy Clin Immunol (2015) 0.92
Remodeling and fibrosis in chronic eosinophil inflammation. Dig Dis (2014) 0.88
Health-related quality of life over time in children with eosinophilic esophagitis and their families. J Pediatr Gastroenterol Nutr (2014) 0.85
White Paper AGA: Eosinophilic Esophagitis. Clin Gastroenterol Hepatol (2017) 0.85
Eosinophilic esophagitis: historical perspective on an evolving disease. Gastroenterol Clin North Am (2014) 0.84
Management of refractory eosinophilic esophagitis. Dig Dis (2014) 0.82
Elimination diets in the management of eosinophilic esophagitis. J Asthma Allergy (2014) 0.78
Unmet therapeutic needs in eosinophilic esophagitis. Dig Dis (2014) 0.75
Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol (2016) 0.75
Combination Steroid and Test-based Food Elimination for Eosinophilic Esophagitis: A Retrospective Analysis. J Pediatr Gastroenterol Nutr (2017) 0.75
Diet and Stress in Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr (2016) 0.75
Management of refractory eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol (2017) 0.75
Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J (2016) 0.75
Six-Food Elimination Diet and Topical Steroids are Effective for Eosinophilic Esophagitis: A Meta-Regression. Dig Dis Sci (2017) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care (1994) 19.87
PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care (2001) 18.55
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
The PedsQL: measurement model for the pediatric quality of life inventory. Med Care (1999) 11.09
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr (2003) 8.61
The intraclass correlation coefficient as a measure of reliability. Psychol Rep (1966) 7.27
Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res (1995) 6.97
The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and type 1 Diabetes Module. Diabetes Care (2003) 5.62
The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer (2002) 5.30
Eosinophilic esophagitis. N Engl J Med (2004) 4.43
The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum (2002) 3.27
How young can children reliably and validly self-report their health-related quality of life?: an analysis of 8,591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes (2007) 3.23
The PedsQL in pediatric asthma: reliability and validity of the Pediatric Quality of Life Inventory generic core scales and asthma module. J Behav Med (2004) 2.85
The PedsQL 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res (2006) 2.81
Factors influencing agreement between child self-report and parent proxy-reports on the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales. Health Qual Life Outcomes (2006) 2.53
PROMIS Pediatric Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. J Pain (2010) 2.38
Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res (1996) 2.26
An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales. Qual Life Res (2010) 2.25
Factor analysis, causal indicators and quality of life. Qual Life Res (1997) 2.25
The PedsQL in pediatric cerebral palsy: reliability, validity, and sensitivity of the Generic Core Scales and Cerebral Palsy Module. Dev Med Child Neurol (2006) 2.12
Perception of quality of life by patients, partners and treating physicians. Qual Life Res (2000) 2.04
Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res (2010) 1.96
Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res (1993) 1.95
Construction of the Pediatric Asthma Impact Scale (PAIS) for the Patient-Reported Outcomes Measurement Information System (PROMIS). J Asthma (2010) 1.82
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol (2011) 1.82
The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes (2004) 1.60
The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents. Pediatr Clin North Am (2009) 1.54
Pediatric health-related quality of life: Feasibility, reliability and validity of the PedsQL transplant module. Am J Transplant (2010) 1.34
Health-related quality of life across pediatric chronic conditions. J Pediatr (2010) 1.29
Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol (2011) 1.20
The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module. Neuromuscul Disord (2009) 1.17
The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease. Dysphagia (2009) 1.06
Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? Child Care Health Dev (2011) 0.98
Development of the Pediatric Quality of Life Inventory™ Eosinophilic Esophagitis module items: qualitative methods. BMC Gastroenterol (2012) 0.87
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Health-related quality of life of severely obese children and adolescents. JAMA (2003) 6.90
Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol (2010) 5.55
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol (2013) 5.09
Eosinophilic esophagitis. N Engl J Med (2004) 4.43
Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol (2004) 4.33
Variants of DENND1B associated with asthma in children. N Engl J Med (2009) 4.18
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest (2003) 4.08
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05
Eosinophils: biological properties and role in health and disease. Clin Exp Allergy (2008) 3.92
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest (2004) 3.90
Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc (2005) 3.82
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology (2006) 3.68
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2012) 3.45
Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol (2005) 3.34
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol (2007) 3.24
Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol (2003) 3.05
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
Using problem-solving skills training to reduce negative affectivity in mothers of children with newly diagnosed cancer: report of a multisite randomized trial. J Consult Clin Psychol (2005) 3.04
Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology (2008) 2.99
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol (2010) 2.98
Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med (2013) 2.94
Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol (2006) 2.92
Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol (2012) 2.90
MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol (2009) 2.89
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes (2009) 2.59
Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology (2002) 2.52
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials (2009) 2.49
Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet (2010) 2.47
Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics (2010) 2.45
Practical issues in the application of item response theory: a demonstration using items from the pediatric quality of life inventory (PedsQL) 4.0 generic core scales. Med Care (2007) 2.45
TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature (2011) 2.42
Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology (2003) 2.40
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
The PedsQL: reliability and validity of the short-form generic core scales and Asthma Module. Med Care (2005) 2.38
Foxa2 regulates alveolarization and goblet cell hyperplasia. Development (2004) 2.35
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2003) 2.31
Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol (2005) 2.26
An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales. Qual Life Res (2010) 2.25
Development of heart and respiratory rate percentile curves for hospitalized children. Pediatrics (2013) 2.25
IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med (2008) 2.19
Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol (2008) 2.19
Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol (2007) 2.18
Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest (2003) 2.17
Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics (2012) 2.16
Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol (2011) 2.16
Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol (2008) 2.12
The use of focus groups in the development of the PROMIS pediatrics item bank. Qual Life Res (2008) 2.07
IL-5 promotes eosinophil trafficking to the esophagus. J Immunol (2002) 2.06
Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol (2003) 2.06
Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med (2002) 2.04
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol (2008) 2.04
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol (2010) 2.00
MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol (2011) 2.00
Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr (2013) 1.98
Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med (2009) 1.97
Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res (2010) 1.96
Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol (2010) 1.92